Does consumer demand pull scientifically novel drug innovation?
The RAND Journal of Economics · 2022-09 · 53 (3) · 590-638
DOI: 10.1111/1756-2171.12422 ↗Kurz gefasst
Fachartikel in der Zeitschrift The RAND Journal of Economics, online erschienen am 18.08.2022. Verfasst von David Dranove und 2 weiteren Autor:innen. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Abstract (Originalsprache)
Prior literature shows that stronger consumer demand leads to increased pharmaceutical R&D. However, how strong these “demand‐pull” effects are for more scientifically novel drug innovation remains unknown. We address this question using comprehensive clinical trial data that include precise characterizations of the scientific approaches used in tested molecules. We characterize scientific novelty as the number of times each approach has been used in the past. Exploiting exogenous demand variation introduced by the introduction of Medicare Part D, we find strong evidence that demand‐pull effects are markedly skewed in favor of non‐novel or “follow‐on” drug R&D.
Zitieren
APA
Dranove, D., Garthwaite, C., & Hermosilla, M. (2022). Does consumer demand pull scientifically novel drug innovation?. The RAND Journal of Economics, 53(3), 590-638. https://doi.org/10.1111/1756-2171.12422
Vancouver
Dranove D, Garthwaite C, Hermosilla M. Does consumer demand pull scientifically novel drug innovation?. The RAND Journal of Economics. 2022;53(3):590-638. doi:10.1111/1756-2171.12422
BibTeX
@article{Dranove2022,
author = {Dranove, David and Garthwaite, Craig and Hermosilla, Manuel},
title = {Does consumer demand pull scientifically novel drug innovation?},
journal = {The RAND Journal of Economics},
year = {2022},
volume = {53},
number = {3},
pages = {590--638},
doi = {10.1111/1756-2171.12422}
}
EUVIMED